{"transactions":[{"id":4630951,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-05T21:36:37.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":233040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-414500","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526414500/ownership.xml","form_type":"4"}},{"id":4630950,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-10-05T21:36:37.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":600,"price":25.32,"value":15192.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-414500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526414500/ownership.xml","form_type":"4"}},{"id":4630949,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-10-05T21:36:37.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":26400,"price":24.4547,"value":645604.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":116343,"source":{"system":"sec-edgar","filing":"0001193125-26-414500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526414500/ownership.xml","form_type":"4"}},{"id":4630948,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-10-05T21:36:37.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-414500","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526414500/ownership.xml","form_type":"4"}},{"id":4626479,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":51341,"kind":"person","name":"Newcomb Jessica","position":1,"cik":"0002130408","reported_name":"Newcomb Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-24T23:41:58.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":2400,"price":25.1718,"value":60412.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $24.59 to $25.56 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The amount reported in Column 2 includes 43,666 unvested restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":59121,"source":{"system":"sec-edgar","filing":"0001193125-26-401327","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2130408/000119312526401327/ownership.xml","form_type":"4"}},{"id":4626478,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":51341,"kind":"person","name":"Newcomb Jessica","position":1,"cik":"0002130408","reported_name":"Newcomb Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-24T23:41:58.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":5100,"price":23.9683,"value":122238.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $23.52 to $24.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The amount reported in Column 2 includes 43,666 unvested restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":61521,"source":{"system":"sec-edgar","filing":"0001193125-26-401327","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2130408/000119312526401327/ownership.xml","form_type":"4"}},{"id":4626477,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":51341,"kind":"person","name":"Newcomb Jessica","position":1,"cik":"0002130408","reported_name":"Newcomb Jessica","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-09-24T23:41:58.000Z","date":"2026-09-22","kind":"sale","planned":true,"acquired":false,"shares":700,"price":22.8029,"value":15962.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on June 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $22.37 to $23.32 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The amount reported in Column 2 includes 43,666 unvested restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer."}],"balance_after":66621,"source":{"system":"sec-edgar","filing":"0001193125-26-401327","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2130408/000119312526401327/ownership.xml","form_type":"4"}},{"id":1821,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:01:04.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":260040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-381853","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526381853/ownership.xml","form_type":"4"}},{"id":1820,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:01:04.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":27000,"price":22.367,"value":603909.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $22.08 to $22.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-381853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526381853/ownership.xml","form_type":"4"}},{"id":1819,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-09-03T20:01:04.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-381853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1825445/000119312526381853/ownership.xml","form_type":"4"}},{"id":695828,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-05T20:01:03.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":287040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-335002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526335002/ownership.xml","form_type":"4"}},{"id":695827,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-08-05T20:01:03.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":21733,"price":27.3509,"value":594417.1097,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $27.17 to $27.78 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-335002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526335002/ownership.xml","form_type":"4"}},{"id":695826,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-08-05T20:01:03.000Z","date":"2026-08-03","kind":"sale","planned":true,"acquired":false,"shares":5267,"price":26.7895,"value":141100.2965,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $26.17 to $27.16 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":137476,"source":{"system":"sec-edgar","filing":"0001193125-26-335002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526335002/ownership.xml","form_type":"4"}},{"id":695825,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-08-05T20:01:03.000Z","date":"2026-08-03","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-335002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526335002/ownership.xml","form_type":"4"}},{"id":718213,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T23:23:37.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":314040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-295124","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526295124/ownership.xml","form_type":"4"}},{"id":718212,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-07-02T23:23:37.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":7371,"price":30.2464,"value":222946.2144,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $29.72 to $30.65 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-295124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526295124/ownership.xml","form_type":"4"}},{"id":718211,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-07-02T23:23:37.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":19629,"price":29.3424,"value":575961.9696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $28.715 to $29.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":123114,"source":{"system":"sec-edgar","filing":"0001193125-26-295124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526295124/ownership.xml","form_type":"4"}},{"id":718210,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-07-02T23:23:37.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-295124","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526295124/ownership.xml","form_type":"4"}},{"id":729235,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T22:10:39.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":35910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":35910,"derivative":{"exercise_price":27.97,"expiration_date":"2036-06-19","underlying":"Common Stock","underlying_shares":35910},"source":{"system":"sec-edgar","filing":"0001193125-26-279871","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526279871/ownership.xml","form_type":"4"}},{"id":729234,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33784,"kind":"person","name":"Azelby Robert","position":1,"cik":"0001656998","reported_name":"Azelby Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T22:10:39.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":5740,"source":{"system":"sec-edgar","filing":"0001193125-26-279871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526279871/ownership.xml","form_type":"4"}},{"id":746382,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40538,"kind":"person","name":"Ketchum John B","position":1,"cik":"0001991806","reported_name":"Ketchum John B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T22:08:23.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":20.22,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-262227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526262227/ownership.xml","form_type":"4"}},{"id":746381,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40538,"kind":"person","name":"Ketchum John B","position":1,"cik":"0001991806","reported_name":"Ketchum John B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T22:08:23.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":24937,"source":{"system":"sec-edgar","filing":"0001193125-26-262227","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526262227/ownership.xml","form_type":"4"}},{"id":746378,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T22:01:28.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":20.22,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-262205","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526262205/ownership.xml","form_type":"4"}},{"id":746377,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T22:01:28.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":16500,"source":{"system":"sec-edgar","filing":"0001193125-26-262205","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526262205/ownership.xml","form_type":"4"}},{"id":746380,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40537,"kind":"person","name":"Rothenberg Mace","position":1,"cik":"0001873988","reported_name":"Rothenberg Mace","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T21:55:25.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":20.22,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001193125-26-262191","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526262191/ownership.xml","form_type":"4"}},{"id":746379,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40537,"kind":"person","name":"Rothenberg Mace","position":1,"cik":"0001873988","reported_name":"Rothenberg Mace","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T21:55:25.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":41500,"source":{"system":"sec-edgar","filing":"0001193125-26-262191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526262191/ownership.xml","form_type":"4"}},{"id":747142,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33455,"kind":"person","name":"Lee Sung","position":1,"cik":"0001793200","reported_name":"Lee Sung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T21:49:24.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":3570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":3570,"derivative":{"exercise_price":20.22,"expiration_date":"2036-06-05","underlying":"Common Stock","underlying_shares":3570},"source":{"system":"sec-edgar","filing":"0001193125-26-262172","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1793200/000119312526262172/ownership.xml","form_type":"4"}},{"id":747141,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33455,"kind":"person","name":"Lee Sung","position":1,"cik":"0001793200","reported_name":"Lee Sung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-08T21:49:24.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":22870,"source":{"system":"sec-edgar","filing":"0001193125-26-262172","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1793200/000119312526262172/ownership.xml","form_type":"4"}},{"id":751938,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T22:37:29.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":341040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-255940","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526255940/ownership.xml","form_type":"4"}},{"id":751937,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-06-03T22:37:29.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":20860,"price":23.0558,"value":480943.988,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $22.60 to $23.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-255940","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526255940/ownership.xml","form_type":"4"}},{"id":751936,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-06-03T22:37:29.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":6140,"price":22.252,"value":136627.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $21.58 to $22.57 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":136603,"source":{"system":"sec-edgar","filing":"0001193125-26-255940","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526255940/ownership.xml","form_type":"4"}},{"id":751935,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-06-03T22:37:29.000Z","date":"2026-06-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-255940","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526255940/ownership.xml","form_type":"4"}},{"id":791841,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T23:47:10.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":368040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-207096","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207096/ownership.xml","form_type":"4"}},{"id":791840,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-05-05T23:47:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":21.9964,"value":24196.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $21.80 to $22.20 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":115743,"source":{"system":"sec-edgar","filing":"0001193125-26-207096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207096/ownership.xml","form_type":"4"}},{"id":791839,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-05-05T23:47:10.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":25900,"price":21.1931,"value":548901.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $20.79 to $21.755 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":116843,"source":{"system":"sec-edgar","filing":"0001193125-26-207096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207096/ownership.xml","form_type":"4"}},{"id":791838,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-05-05T23:47:10.000Z","date":"2026-05-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,121 shares that were acquired on November 1, 2025 pursuant to the Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)."}],"balance_after":142743,"source":{"system":"sec-edgar","filing":"0001193125-26-207096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207096/ownership.xml","form_type":"4"}},{"id":791825,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":49667,"kind":"person","name":"Gall Matthew","position":1,"cik":"0001816194","reported_name":"Gall Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-05T23:46:28.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on April 15, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":240000,"derivative":{"exercise_price":20.98,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001193125-26-207094","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207094/ownership.xml","form_type":"4"}},{"id":791824,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":49667,"kind":"person","name":"Gall Matthew","position":1,"cik":"0001816194","reported_name":"Gall Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T23:46:28.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs shall vest over a three-year period at a rate of (i) 13,200 RSUs on or about May 10, 2027, (ii) 13,200 RSUs on or about May 10, 2028 and (iii) 13,600 RSUs on or about May 9, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001193125-26-207094","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526207094/ownership.xml","form_type":"4"}},{"id":796311,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33455,"kind":"person","name":"Lee Sung","position":1,"cik":"0001793200","reported_name":"Lee Sung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-01T21:26:21.000Z","date":"2026-04-29","kind":"grant","planned":false,"acquired":true,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years commencing on January 2, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. The options were granted in connection with the Reporting Person's service on the Issuer's board of directors and reflect the value the Reporting Person is entitled to pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":5200,"derivative":{"exercise_price":22.06,"expiration_date":"2036-04-29","underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001193125-26-201749","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1793200/000119312526201749/ownership.xml","form_type":"4"}},{"id":796310,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33455,"kind":"person","name":"Lee Sung","position":1,"cik":"0001793200","reported_name":"Lee Sung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-01T21:26:21.000Z","date":"2026-04-29","kind":"grant","planned":false,"acquired":true,"shares":12300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments on January 2, 2027, January 2, 2028 and January 2, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. The RSUs were granted in connection with the Reporting Person's service on the Issuer's board of directors and reflect the value the Reporting Person is entitled to pursuant to the Issuer's Non-Employee Director Compensation Policy."}],"balance_after":22300,"source":{"system":"sec-edgar","filing":"0001193125-26-201749","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1793200/000119312526201749/ownership.xml","form_type":"4"}},{"id":807169,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T00:14:04.000Z","date":"2026-04-15","kind":"exercise","planned":true,"acquired":false,"shares":38460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":395040,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":38460},"source":{"system":"sec-edgar","filing":"0001193125-26-159747","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526159747/ownership.xml","form_type":"4"}},{"id":807168,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-04-17T00:14:04.000Z","date":"2026-04-15","kind":"sale","planned":true,"acquired":false,"shares":38460,"price":25,"value":961500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":112622,"source":{"system":"sec-edgar","filing":"0001193125-26-159747","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526159747/ownership.xml","form_type":"4"}},{"id":807167,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-04-17T00:14:04.000Z","date":"2026-04-15","kind":"exercise","planned":true,"acquired":true,"shares":38460,"price":5.2,"value":199992.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":151082,"source":{"system":"sec-edgar","filing":"0001193125-26-159747","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526159747/ownership.xml","form_type":"4"}},{"id":819783,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T00:09:07.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":433500,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":27000},"source":{"system":"sec-edgar","filing":"0001193125-26-140874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526140874/ownership.xml","form_type":"4"}},{"id":819782,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-04-03T00:09:07.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":27000,"price":21.2029,"value":572478.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":112622,"source":{"system":"sec-edgar","filing":"0001193125-26-140874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526140874/ownership.xml","form_type":"4"}},{"id":819781,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-04-03T00:09:07.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":27000,"price":5.2,"value":140400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":139622,"source":{"system":"sec-edgar","filing":"0001193125-26-140874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526140874/ownership.xml","form_type":"4"}},{"id":826434,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-28T00:06:56.000Z","date":"2026-03-25","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":460500,"derivative":{"exercise_price":5.2,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001193125-26-129990","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526129990/ownership.xml","form_type":"4"}},{"id":826433,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-03-28T00:06:56.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":12000,"price":20.11,"value":241320.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.27, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":112622,"source":{"system":"sec-edgar","filing":"0001193125-26-129990","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526129990/ownership.xml","form_type":"4"}},{"id":826432,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-03-28T00:06:56.000Z","date":"2026-03-25","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":5.2,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":124622,"source":{"system":"sec-edgar","filing":"0001193125-26-129990","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526129990/ownership.xml","form_type":"4"}},{"id":853660,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-03-09T20:01:04.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":20251,"price":15,"value":303765.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."}],"balance_after":112622,"source":{"system":"sec-edgar","filing":"0001193125-26-098443","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526098443/ownership.xml","form_type":"4"}},{"id":877410,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-27T23:54:34.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":54345,"price":12.7741,"value":694208.4645,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $12.61 to $13.09 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":132873,"source":{"system":"sec-edgar","filing":"0001193125-26-083579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526083579/ownership.xml","form_type":"4"}},{"id":919552,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":38785,"kind":"person","name":"Beckman Daniella","position":1,"cik":"0001513422","reported_name":"Beckman Daniella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T01:12:01.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":265980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":265980,"derivative":{"exercise_price":11.94,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":265980},"source":{"system":"sec-edgar","filing":"0001193125-26-038072","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038072/ownership.xml","form_type":"4"}},{"id":919551,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":38785,"kind":"person","name":"Beckman Daniella","position":1,"cik":"0001513422","reported_name":"Beckman Daniella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:12:01.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":113,"price":12.8971,"value":1457.3723,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":184297,"source":{"system":"sec-edgar","filing":"0001193125-26-038072","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038072/ownership.xml","form_type":"4"}},{"id":919550,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":38785,"kind":"person","name":"Beckman Daniella","position":1,"cik":"0001513422","reported_name":"Beckman Daniella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:12:01.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":10204,"price":12.2573,"value":125073.4892,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":184410,"source":{"system":"sec-edgar","filing":"0001193125-26-038072","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038072/ownership.xml","form_type":"4"}},{"id":919549,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":38785,"kind":"person","name":"Beckman Daniella","position":1,"cik":"0001513422","reported_name":"Beckman Daniella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T01:12:01.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":44330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":194614,"source":{"system":"sec-edgar","filing":"0001193125-26-038072","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038072/ownership.xml","form_type":"4"}},{"id":919548,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":39295,"kind":"person","name":"Weber Barbara","position":1,"cik":"0001800670","reported_name":"Weber Barbara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director, Executive Chair"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T01:09:06.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":222132,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest and become exercisable in 12 equal monthly installments following January 1, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":222132,"derivative":{"exercise_price":11.94,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":222132},"source":{"system":"sec-edgar","filing":"0001193125-26-038070","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038070/ownership.xml","form_type":"4"}},{"id":919547,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":39295,"kind":"person","name":"Weber Barbara","position":1,"cik":"0001800670","reported_name":"Weber Barbara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director, Executive Chair"}}],"security":"Common Stock","published_at":"2026-02-05T01:09:06.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":333,"price":12.8971,"value":4294.7343,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":1629254,"source":{"system":"sec-edgar","filing":"0001193125-26-038070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038070/ownership.xml","form_type":"4"}},{"id":919546,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":39295,"kind":"person","name":"Weber Barbara","position":1,"cik":"0001800670","reported_name":"Weber Barbara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director, Executive Chair"}}],"security":"Common Stock","published_at":"2026-02-05T01:09:06.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":30186,"price":12.2573,"value":369998.8578,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":1629587,"source":{"system":"sec-edgar","filing":"0001193125-26-038070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038070/ownership.xml","form_type":"4"}},{"id":919545,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":39295,"kind":"person","name":"Weber Barbara","position":1,"cik":"0001800670","reported_name":"Weber Barbara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director, Executive Chair"}}],"security":"Common Stock","published_at":"2026-02-05T01:09:06.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":37522,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in full on February 1, 2027, subject to the Reporting Person's continuous service with the Issuer as of such vesting date."}],"balance_after":1659773,"source":{"system":"sec-edgar","filing":"0001193125-26-038070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038070/ownership.xml","form_type":"4"}},{"id":919540,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-05T01:02:17.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":284760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2027 with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":284760,"derivative":{"exercise_price":11.94,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":284760},"source":{"system":"sec-edgar","filing":"0001193125-26-038052","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038052/ownership.xml","form_type":"4"}},{"id":919539,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:17.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":201,"price":12.8971,"value":2592.3171,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $12.88 to $12.91 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":187218,"source":{"system":"sec-edgar","filing":"0001193125-26-038052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038052/ownership.xml","form_type":"4"}},{"id":919538,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:17.000Z","date":"2026-02-03","kind":"sale","planned":false,"acquired":false,"shares":18251,"price":12.2573,"value":223707.9823,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $11.88 to $12.875 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":187419,"source":{"system":"sec-edgar","filing":"0001193125-26-038052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038052/ownership.xml","form_type":"4"}},{"id":919537,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D"}}],"security":"Common Stock","published_at":"2026-02-05T01:02:17.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":47460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":205670,"source":{"system":"sec-edgar","filing":"0001193125-26-038052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526038052/ownership.xml","form_type":"4"}},{"id":941100,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":69524,"kind":"person","name":"Peters Malte","position":1,"cik":"0001876563","reported_name":"Peters Malte","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-12T11:15:20.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":1650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, with 25% vesting on January 8, 2027 and the remaining option shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":1650000,"derivative":{"exercise_price":11.06,"expiration_date":"2036-01-08","underlying":"Common Stock","underlying_shares":1650000},"source":{"system":"sec-edgar","filing":"0001193125-26-009663","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526009663/ownership.xml","form_type":"4"}},{"id":941099,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":69524,"kind":"person","name":"Peters Malte","position":1,"cik":"0001876563","reported_name":"Peters Malte","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-12T11:15:20.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 1, 2027, 33% on February 14, 2028 and 34% on February 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":367500,"source":{"system":"sec-edgar","filing":"0001193125-26-009663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526009663/ownership.xml","form_type":"4"}},{"id":948976,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33455,"kind":"person","name":"Lee Sung","position":1,"cik":"0001793200","reported_name":"Lee Sung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-06T21:10:04.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":8.93,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-004433","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1793200/000119312526004433/ownership.xml","form_type":"4"}},{"id":948975,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":33455,"kind":"person","name":"Lee Sung","position":1,"cik":"0001793200","reported_name":"Lee Sung","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:10:04.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments following the grant date, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-004433","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1793200/000119312526004433/ownership.xml","form_type":"4"}},{"id":1008297,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":69524,"kind":"person","name":"Peters Malte","position":1,"cik":"0001876563","reported_name":"Peters Malte","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-04T14:25:50.000Z","date":"2025-11-03","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 48 substantially equal monthly installments over a period of four years, with the first vesting date on December 3, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":150000,"derivative":{"exercise_price":8.01,"expiration_date":"2035-11-03","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193125-25-263710","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312525263710/ownership.xml","form_type":"4"}},{"id":1013277,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":73568,"kind":"organization","name":"Third Rock Ventures IV, L.P.","position":1,"cik":"0001688327","reported_name":"Third Rock Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73569,"kind":"organization","name":"Third Rock Ventures GP IV, L.P.","position":2,"cik":"0001688326","reported_name":"Third Rock Ventures GP IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73570,"kind":"organization","name":"TRV GP IV, LLC","position":3,"cik":"0001688325","reported_name":"TRV GP IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-27T20:15:03.000Z","date":"2025-10-23","kind":"sale","planned":false,"acquired":false,"shares":477401,"price":10.152,"value":4846574.952,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are directly held by Third Rock Ventures IV, L.P. (\"TRV IV\"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. (\"TRV GP IV\"). The general partner of TRV GP IV is TRV GP IV, LLC (\"TRV GP IV LLC\"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":13386574,"source":{"system":"sec-edgar","filing":"0001193125-25-251606","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312525251606/ownership.xml","form_type":"4"}},{"id":1031269,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":73568,"kind":"organization","name":"Third Rock Ventures IV, L.P.","position":1,"cik":"0001688327","reported_name":"Third Rock Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73569,"kind":"organization","name":"Third Rock Ventures GP IV, L.P.","position":2,"cik":"0001688326","reported_name":"Third Rock Ventures GP IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73570,"kind":"organization","name":"TRV GP IV, LLC","position":3,"cik":"0001688325","reported_name":"TRV GP IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-29T20:15:05.000Z","date":"2025-09-25","kind":"sale","planned":false,"acquired":false,"shares":500000,"price":8.017,"value":4008500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or\nthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are directly held by Third Rock Ventures IV, L.P. (\"TRV IV\"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. (\"TRV GP IV\"). The general partner of TRV GP IV is TRV GP IV, LLC (\"TRV GP IV LLC\"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":13863975,"source":{"system":"sec-edgar","filing":"0001193125-25-223227","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312525223227/ownership.xml","form_type":"4"}},{"id":1037925,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":73568,"kind":"organization","name":"Third Rock Ventures IV, L.P.","position":1,"cik":"0001688327","reported_name":"Third Rock Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73569,"kind":"organization","name":"Third Rock Ventures GP IV, L.P.","position":2,"cik":"0001688326","reported_name":"Third Rock Ventures GP IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73570,"kind":"organization","name":"TRV GP IV, LLC","position":3,"cik":"0001688325","reported_name":"TRV GP IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-17T22:06:13.000Z","date":"2025-09-16","kind":"sale","planned":false,"acquired":false,"shares":363541,"price":7.04,"value":2559328.64,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are directly held by Third Rock Ventures IV, L.P. (\"TRV IV\"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. (\"TRV GP IV\"). The general partner of TRV GP IV is TRV GP IV, LLC (\"TRV GP IV LLC\"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":14363975,"source":{"system":"sec-edgar","filing":"0001193125-25-206453","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312525206453/ownership.xml","form_type":"4"}},{"id":1044892,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":73568,"kind":"organization","name":"Third Rock Ventures IV, L.P.","position":1,"cik":"0001688327","reported_name":"Third Rock Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73569,"kind":"organization","name":"Third Rock Ventures GP IV, L.P.","position":2,"cik":"0001688326","reported_name":"Third Rock Ventures GP IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73570,"kind":"organization","name":"TRV GP IV, LLC","position":3,"cik":"0001688325","reported_name":"TRV GP IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-09T20:15:06.000Z","date":"2025-09-08","kind":"sale","planned":false,"acquired":false,"shares":86459,"price":7.0395,"value":608628.1305,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are directly held by Third Rock Ventures IV, L.P. (\"TRV IV\"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. (\"TRV GP IV\"). The general partner of TRV GP IV is TRV GP IV, LLC (\"TRV GP IV LLC\"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":14727516,"source":{"system":"sec-edgar","filing":"0001193125-25-199177","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312525199177/ownership.xml","form_type":"4"}},{"id":1044891,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":73568,"kind":"organization","name":"Third Rock Ventures IV, L.P.","position":1,"cik":"0001688327","reported_name":"Third Rock Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73569,"kind":"organization","name":"Third Rock Ventures GP IV, L.P.","position":2,"cik":"0001688326","reported_name":"Third Rock Ventures GP IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73570,"kind":"organization","name":"TRV GP IV, LLC","position":3,"cik":"0001688325","reported_name":"TRV GP IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-09T20:15:06.000Z","date":"2025-09-05","kind":"sale","planned":false,"acquired":false,"shares":642906,"price":7,"value":4500342.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"These shares are directly held by Third Rock Ventures IV, L.P. (\"TRV IV\"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. (\"TRV GP IV\"). The general partner of TRV GP IV is TRV GP IV, LLC (\"TRV GP IV LLC\"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":14813975,"source":{"system":"sec-edgar","filing":"0001193125-25-199177","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312525199177/ownership.xml","form_type":"4"}},{"id":1055817,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":73568,"kind":"organization","name":"Third Rock Ventures IV, L.P.","position":1,"cik":"0001688327","reported_name":"Third Rock Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73569,"kind":"organization","name":"Third Rock Ventures GP IV, L.P.","position":2,"cik":"0001688326","reported_name":"Third Rock Ventures GP IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73570,"kind":"organization","name":"TRV GP IV, LLC","position":3,"cik":"0001688325","reported_name":"TRV GP IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-26T20:15:09.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":302194,"price":7,"value":2115358.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are directly held by Third Rock Ventures IV, L.P. (\"TRV IV\"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. (\"TRV GP IV\"). The general partner of TRV GP IV is TRV GP IV, LLC (\"TRV GP IV LLC\"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":15456881,"source":{"system":"sec-edgar","filing":"0000950170-25-111457","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025111457/ownership.xml","form_type":"4"}},{"id":1059319,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":73568,"kind":"organization","name":"Third Rock Ventures IV, L.P.","position":1,"cik":"0001688327","reported_name":"Third Rock Ventures IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73569,"kind":"organization","name":"Third Rock Ventures GP IV, L.P.","position":2,"cik":"0001688326","reported_name":"Third Rock Ventures GP IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":73570,"kind":"organization","name":"TRV GP IV, LLC","position":3,"cik":"0001688325","reported_name":"TRV GP IV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-08-21T20:15:14.000Z","date":"2025-08-19","kind":"sale","planned":false,"acquired":false,"shares":1100000,"price":7.0116,"value":7712760.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are directly held by Third Rock Ventures IV, L.P. (\"TRV IV\"). The general partner of TRV IV is Third Rock Ventures GP IV, L.P. (\"TRV GP IV\"). The general partner of TRV GP IV is TRV GP IV, LLC (\"TRV GP IV LLC\"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":15759075,"source":{"system":"sec-edgar","filing":"0000950170-25-110662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025110662/ownership.xml","form_type":"4"}},{"id":1118089,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":69524,"kind":"person","name":"Peters Malte","position":1,"cik":"0001876563","reported_name":"Peters Malte","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T21:51:20.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":3.51,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000950170-25-083912","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083912/ownership.xml","form_type":"4"}},{"id":1118088,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":69524,"kind":"person","name":"Peters Malte","position":1,"cik":"0001876563","reported_name":"Peters Malte","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:51:20.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0000950170-25-083912","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083912/ownership.xml","form_type":"4"}},{"id":1118087,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T21:50:27.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":3.51,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000950170-25-083911","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083911/ownership.xml","form_type":"4"}},{"id":1118086,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40536,"kind":"person","name":"Calhoun Lesley Ann","position":1,"cik":"0001730866","reported_name":"Calhoun Lesley Ann","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:50:27.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0000950170-25-083911","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083911/ownership.xml","form_type":"4"}},{"id":1118085,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40537,"kind":"person","name":"Rothenberg Mace","position":1,"cik":"0001873988","reported_name":"Rothenberg Mace","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T21:47:25.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":3.51,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000950170-25-083907","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083907/ownership.xml","form_type":"4"}},{"id":1118084,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40537,"kind":"person","name":"Rothenberg Mace","position":1,"cik":"0001873988","reported_name":"Rothenberg Mace","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:47:25.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":37500,"source":{"system":"sec-edgar","filing":"0000950170-25-083907","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083907/ownership.xml","form_type":"4"}},{"id":1118083,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40538,"kind":"person","name":"Ketchum John B","position":1,"cik":"0001991806","reported_name":"Ketchum John B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T21:47:17.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":3.51,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000950170-25-083906","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083906/ownership.xml","form_type":"4"}},{"id":1118082,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":40538,"kind":"person","name":"Ketchum John B","position":1,"cik":"0001991806","reported_name":"Ketchum John B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:47:17.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":20937,"source":{"system":"sec-edgar","filing":"0000950170-25-083906","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083906/ownership.xml","form_type":"4"}},{"id":1118081,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T21:45:23.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":37500,"derivative":{"exercise_price":3.51,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000950170-25-083903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083903/ownership.xml","form_type":"4"}},{"id":1118080,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":35925,"kind":"person","name":"Borisy Alexis","position":1,"cik":"0001319446","reported_name":"Borisy Alexis","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T21:45:23.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0000950170-25-083903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025083903/ownership.xml","form_type":"4"}},{"id":1280377,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":83527,"kind":"person","name":"Barry Douglas","position":1,"cik":"0001890662","reported_name":"Barry Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-02-07T01:21:04.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":2556,"price":3.1614,"value":8080.5384,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $3.00 to $3.245 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":66014,"source":{"system":"sec-edgar","filing":"0000950170-25-015704","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015704/ownership.xml","form_type":"4"}},{"id":1280376,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":83527,"kind":"person","name":"Barry Douglas","position":1,"cik":"0001890662","reported_name":"Barry Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-02-07T01:21:04.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":2774,"price":2.988,"value":8288.712,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $2.86 to $3.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":68570,"source":{"system":"sec-edgar","filing":"0000950170-25-015704","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015704/ownership.xml","form_type":"4"}},{"id":1280375,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":38785,"kind":"person","name":"Beckman Daniella","position":1,"cik":"0001513422","reported_name":"Beckman Daniella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:10:55.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":3948,"price":3.1614,"value":12481.2072,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from  $3.00 to $3.245 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":150284,"source":{"system":"sec-edgar","filing":"0000950170-25-015696","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015696/ownership.xml","form_type":"4"}},{"id":1280374,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":38785,"kind":"person","name":"Beckman Daniella","position":1,"cik":"0001513422","reported_name":"Beckman Daniella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:10:55.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":4284,"price":2.988,"value":12800.592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $2.86 to $3.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":154232,"source":{"system":"sec-edgar","filing":"0000950170-25-015696","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015696/ownership.xml","form_type":"4"}},{"id":1280373,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-07T01:08:43.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":6851,"price":3.1614,"value":21658.7514,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from  $3.00 to $3.245 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":158210,"source":{"system":"sec-edgar","filing":"0000950170-25-015693","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015693/ownership.xml","form_type":"4"}},{"id":1280372,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-07T01:08:43.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":7432,"price":2.988,"value":22206.816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $2.86 to $3.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":165061,"source":{"system":"sec-edgar","filing":"0000950170-25-015693","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015693/ownership.xml","form_type":"4"}},{"id":1280371,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":39295,"kind":"person","name":"Weber Barbara","position":1,"cik":"0001800670","reported_name":"Weber Barbara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:02:12.000Z","date":"2025-02-05","kind":"sale","planned":false,"acquired":false,"shares":9013,"price":3.1614,"value":28493.6982,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $3.00 to $3.245 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":1622251,"source":{"system":"sec-edgar","filing":"0000950170-25-015684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015684/ownership.xml","form_type":"4"}},{"id":1280370,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":39295,"kind":"person","name":"Weber Barbara","position":1,"cik":"0001800670","reported_name":"Weber Barbara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-07T01:02:12.000Z","date":"2025-02-04","kind":"sale","planned":false,"acquired":false,"shares":9778,"price":2.988,"value":29216.664,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Issuer has adopted a \"sell-to-cover\" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $2.86 to $3.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":1631264,"source":{"system":"sec-edgar","filing":"0000950170-25-015684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025015684/ownership.xml","form_type":"4"}},{"id":1282071,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":38785,"kind":"person","name":"Beckman Daniella","position":1,"cik":"0001513422","reported_name":"Beckman Daniella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T01:14:53.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":156713,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":156713,"derivative":{"exercise_price":2.91,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":156713},"source":{"system":"sec-edgar","filing":"0000950170-25-014840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025014840/ownership.xml","form_type":"4"}},{"id":1282070,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":38785,"kind":"person","name":"Beckman Daniella","position":1,"cik":"0001513422","reported_name":"Beckman Daniella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-06T01:14:53.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":26119,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 2, 2026, 33% on February 1, 2027 and 34% on February 14, 2028, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":158516,"source":{"system":"sec-edgar","filing":"0000950170-25-014840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025014840/ownership.xml","form_type":"4"}},{"id":1282075,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T00:34:09.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":318090,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":318090,"derivative":{"exercise_price":2.91,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":318090},"source":{"system":"sec-edgar","filing":"0000950170-25-014813","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025014813/ownership.xml","form_type":"4"}},{"id":1282074,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":1498,"kind":"person","name":"Crystal Adam","position":1,"cik":"0001825445","reported_name":"Crystal Adam","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-02-06T00:34:09.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":53015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 2, 2026, 33% on February 1, 2027 and 34% on February 14, 2028, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":172493,"source":{"system":"sec-edgar","filing":"0000950170-25-014813","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025014813/ownership.xml","form_type":"4"}},{"id":1282073,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":39295,"kind":"person","name":"Weber Barbara","position":1,"cik":"0001800670","reported_name":"Weber Barbara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T00:31:35.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":635250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":635250,"derivative":{"exercise_price":2.91,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":635250},"source":{"system":"sec-edgar","filing":"0000950170-25-014810","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025014810/ownership.xml","form_type":"4"}},{"id":1282072,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":39295,"kind":"person","name":"Weber Barbara","position":1,"cik":"0001800670","reported_name":"Weber Barbara","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-06T00:31:35.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":105875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest over a three year period at a rate of 33% on February 2, 2026, 33% on February 1, 2027 and 34% on February 14, 2028, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date."}],"balance_after":1641042,"source":{"system":"sec-edgar","filing":"0000950170-25-014810","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025014810/ownership.xml","form_type":"4"}},{"id":1282069,"issuer":{"id":1497,"kind":"organization","name":"Tango Therapeutics, Inc.","symbol":"TNGX"},"owners":[{"id":83527,"kind":"person","name":"Barry Douglas","position":1,"cik":"0001890662","reported_name":"Barry Douglas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T00:30:12.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":164175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter."}],"balance_after":164175,"derivative":{"exercise_price":2.91,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":164175},"source":{"system":"sec-edgar","filing":"0000950170-25-014808","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1819133/000095017025014808/ownership.xml","form_type":"4"}}],"next_cursor":"2025-02-06T00:30:12.000000Z,1282069"}